Yet Another Research Firm has Initiated Coverage on Cellectis S.A. – American Depositary Shares (NASDAQ:CLLS)

March 17, 2018 - By Graig Alexander

 Yet Another Research Firm has Initiated Coverage on Cellectis S.A.   American Depositary Shares (NASDAQ:CLLS)

How Guggenheim Currently Rates Cellectis S.A. – American Depositary Shares (NASDAQ:CLLS)

In a research note revealed to investors on Friday, 16 March, Guggenheim analyst just initiated coverage of Cellectis S.A. – American Depositary Shares (NASDAQ:CLLS) with Neutral rating.

Cellectis S.A. (NASDAQ:CLLS) Ratings Coverage

Among 8 analysts covering Cellectis (NASDAQ:CLLS), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. Cellectis has $73.0 highest and $20.0 lowest target. $45’s average target is 33.73% above currents $33.65 stock price. Cellectis had 15 analyst reports since April 5, 2016 according to SRatingsIntel. The rating was initiated by Wells Fargo with “Outperform” on Tuesday, February 28. The firm earned “Buy” rating on Wednesday, September 6 by Nomura. As per Friday, June 2, the company rating was maintained by Oppenheimer. The rating was maintained by Jefferies on Thursday, August 24 with “Buy”. SunTrust maintained the stock with “Hold” rating in Friday, October 6 report. The firm has “Buy” rating by Ladenburg Thalmann given on Tuesday, April 5. The firm has “Buy” rating given on Friday, October 27 by Jefferies. The firm has “Hold” rating by SunTrust given on Wednesday, September 6. Jefferies maintained the shares of CLLS in report on Tuesday, June 6 with “Buy” rating. The company was maintained on Wednesday, August 16 by Oppenheimer.

The stock decreased 4.10% or $1.44 during the last trading session, reaching $33.65. About 331,967 shares traded or 78.16% up from the average. Cellectis S.A. (NASDAQ:CLLS) has declined 17.09% since March 17, 2017 and is downtrending. It has underperformed by 33.79% the S&P500.

Analysts await Cellectis S.A. (NASDAQ:CLLS) to report earnings on May, 8. They expect $-0.67 earnings per share, down 19.64 % or $0.11 from last year’s $-0.56 per share. After $-0.76 actual earnings per share reported by Cellectis S.A. for the previous quarter, Wall Street now forecasts -11.84 % EPS growth.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company has market cap of $1.19 billion. The firm operates through two divisions, Therapeutics and Plants. It currently has negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.